Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 known ✓ | P31213 | 9/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 16/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | HSD3B1 | P14060 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finasteride SCHEMBL1560981 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5148287 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL11909 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL13575812 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL3982016 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22032590 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969513 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL6448111 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 55337 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026107401-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF POLYLACTIC ACID FOR HAIR GROWTH | DURAIRAJ KALPNA KAY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| CN-122060683-A | Human mesenchymal stem cell edited by RSPO3 mRNA and application thereof | 四川康德赛医疗科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-117137867-B | Foam type cation nanoemulsion hair growth promoting liquid and preparation method thereof | 苏州大学 | 2026-05-19 | — | — | CN | claimed |
| US-12622907-B2 | Hair loss therapy | NIRMANA HEALTH, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-3426310-B1 | PROSTATIC LIQUID BIOPSY FOR THE DETECTION OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | WAVESENSE INC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-20260115441-A1 | APPARATUS AND METHOD FOR INTRADERMAL DELIVERY OF ACTIVES FOLLOWING PRE-CONDITIONING OF SKIN | VIAS PARTNERS, LLC (US) | 2026-04-30 | — | — | US | claimed |
| EP-0536843-A1 | Antiandrogen-5-alpha-reductase inhibitor compositions and their preparation | STERLING WINTHROP INC. (US) | 1993-04-14 | — | — | EP | claimed |
| US-5175155-A | Antiandrogen for treating prostate disease in male mammals | STERLING WINTHROP INC. (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| EP-0461930-A1 | A crystallization method to improve crystal structure and size | MERCK & CO. INC. (US) | 1991-12-18 | — | — | EP | claimed |
| WO-1991000733-A1 | METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES | ENDORECHERCHE INC. (CA) | 1991-01-24 | — | — | WO | claimed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | claimed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | claimed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | claimed |